IP Library Granted Patent US 10,191,056
Granted Patent B2
US 10,191,056 · App. 14/757,607 · Granted Jan 29, 2019

Diagnostic evaluation of antibody responses to commonly recognized prostate cancer-associated antigens

Inventors: Douglas G. McNeel (Madison, WI); Brett B. Maricque (Green Bay, WI)
Assignee: Wisconsin Alumni Research Foundation
G01N33/57434C40B40/10G01N33/531G01N2800/60
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,191,056
App. No.
14/757,607
Granted
Jan 29, 2019
Kind
B2
Abstract

The present invention relates to a plurality of antigens that together form a panel of immunoreactive molecules suitable for identifying candidates for prostate cancer examination. Methods for identifying antibodies indicative of a pre-malignant or malignant prostate are disclosed. Further disclosed are kits that can be used to practice the above methods.

Claims (6)

1. An antigen panel for identifying immunoreactivity associated with a premalignant or malignant prostate, the panel comprising antigens encoded by SEQ ID NO:5, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:40, SEQ ID NO:44, SEQ ID NO:64, SEQ ID NO:68, SEQ ID NO:72, SEQ ID NO:76, SEQ ID NO:78, SEQ ID NO:80, SEQ ID NO:86, and SEQ ID NO:91, the encoded antigens being immobilized on one of a membrane, a plate, and a filter, and having a positive likelihood ratio of at least 4.

2. The panel of claim 1 , wherein the panel further comprises an antigen encoded by a nucleic acid having a sequence selected from the group consisting of SEQ ID Nos: 1-4, 6-9, 11, 13-16, 21-23, 26-31, 33, 36-39, 31-43, 45-63, 65-67, 69-71, 73-75, 77, 79, 81-85, 87-90, and 92-128.

3. The panel of claim 1 , the panel consisting of antigens encoded by SEQ ID NO:5, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:40, SEQ ID NO:44, SEQ ID NO:64, SEQ ID NO:68, SEQ ID NO:72, SEQ ID NO:76, SEQ ID NO:78, SEQ ID NO:80, SEQ ID NO:86, and SEQ ID NO:91.

4. The panel of claim 1 , wherein at least three of the antigens in the panel elicit an immune response in at least about 9% of individuals with prostatitis or prostate cancer.

5. The panel of claim 1 , wherein each antigen is expressed by a phage and attached to the membrane, plate or filter via the phage.

6. The panel of claim 1 , wherein the plate is a multi-well plate.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 3, 2018
From: MCNEEL, DOUGLAS; MARICQUE, BRETT
To: WISCONSIN ALUMNI RESEARCH FOUNDATION
Reel/Frame 046257/0164 →
CONFIRMATORY LICENSE Recorded May 17, 2018
From: WISCONSIN ALUMNI RESEARCH FOUNDATION
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 046180/0001 →
Continuity (3)
Continuation 13088594 · Apr 18, 2011
Provisional Application 61324953 · Apr 16, 2010
Related Publication 20160238606A1 · Aug 18, 2016
Cited By (1)
US 12,540,361